About Xiamen Amoytop Biotech Company

The company is an innovative biomedical enterprise and a science and technology innovation board listed company mainly engaged in R&D, production and sales of recombinant proteins and long-term modifying drugs. The company takes immune-related cytokine drugs as its main research direction, and is committed to becoming a leader in cytokine drug-based systemic immunity solutions to provide better solutions for the treatment of major diseases such as viral hepatitis and malignant tumors. For some time to come, the company will focus on the field of clinical treatment of chronic hepatitis B while continuing to advance the clinical research progress of several ongoing research projects. The company is an innovative biomedical enterprise mainly engaged in R&D, production and sales of recombinant proteins and long-term modified drugs. The company takes immune-related cytokine drugs as its main research direction, and is committed to becoming a leader in cytokine drug-based systemic immunity solutions to provide better solutions for the treatment of major diseases such as viral hepatitis and malignant tumors. The company currently has five products on the market, namely Pegbin, Peggen, Terli, Terzine, and Telcon. Corporate honors: 2023 Top 100 Innovative Pharmaceutical Enterprises, Top 100 Listed Companies Growing in China, Fujian Top 100 Innovative Private Enterprises, China Silver Diamond Award for Liver Disease Diagnosis and Treatment Technology, National Innovative Enterprise, Fujian Strategic Emerging Industry Key Enterprise, National Torch Program Key High-tech Enterprise, Postdoctoral Research Workstation, etc.